1. $STUDY When you cover a stock after shorting, does that make the stock go up? $GNVC $AXN

  2. 5 Days Up http://www.dailystockplays.com/5-Days-Up-2015-03-24.html $CCE $STO $AUQ $CSIQ $COST $JAKK $ZQK $SSE $PBF $JKS $CTB $CROX $FINL $HOLI $WGO $GNVC $IJR $PCL $AWAY $WWW

  3. GenVec just filed its Annual report [Section 13 and 15(d), not S-K Item 405] http://www.conferencecalltranscripts.org/include/?location=http://www.sec.gov/Archives/edgar/data/934473/000157104915002270/0001571049-15-002270-index.htm $GNVC

  4. $GNVC Genvec Inc files Form 10-K (Annual Reports) SEC Filing.. http://boardvote.com/symbol/GNVC/communique/888686

  5. $GNVC buy reiterated, target set to $8 by Roth Capital. Brief explanation here: https://www.flashratings.com/stories/169920?s=513700

  6. Currently holding some $CYCC $CYTX $DERM $GEVO $GNVC in my trading acct. Let s go!

  7. Revealing admissions stated regarding $GNVC cc transcript http://www.conferencecalltranscripts.org/include/?location=http://seekingalpha.com/article/3025296-genvecs-gnvc-ceo-douglas-swirsky-on-q4-2014-results-earnings-call-transcript

  8. $GNVC 4Q14 Q&A – Peter, Private: CGF166 milestone payment in 2015? CEO: Not anticipate an additional milestone from this program in 2015.

  9. $GNVC 4Q14 Q&A – Julie, Boenning: 3rd patient treated? CEO: Don’t think it’s particularly relevant. Assumption is that trial is continuing.

  10. $GNVC 4Q14 Q&A – Reni, H.C: Other programs? CEO: Program against HSV & effort in Malaria. We’ll wait something specific to say on those.

  11. $GNVC GenVec Reports Fourth Quarter And 2014 Year-End Financial Results http://stocknewsnow.com/news/NEWSID24032015100003/GenVec-Reports-Fourth-Quarter-And-2014-Year-End-Financial-Results

  12. $GNVC 4Q14 Q&A – Joe, Roth: News flow out of CGF166? CSO: Not in position to promise sequence of events that may be revealed by Novartis.

  13. $GNVC 4Q14 Q&A – Joe, Roth: CGF166 phase 2 volume escalation? CSO: The volume goes up & the number of particles of vector go up with it.

  14. $SLTD Gainers: $GNVC +23% $DGLY +19% $VCEL +18% $ISR +11% $ATOS +10% $ABMD +9% $RADA +7% $ARAY +7%

  15. $GNVC 4Q14 Call – Jim, CFO: In FY14: Net loss $2.5MM or $0.16 per share. Revenue $6MM. Cash & cash equivalents & investments $14.7MM.

  16. $GNVC 4Q14 Call – Doug, CEO: Believe key element of GNVC’s future success will be strategy to develop products through collaborations.

  17. $GNVC 4Q14 Call – Doug, CEO: Aligned expenditures with capital resources & working to build portfolio of opportunities through collaboration

  18. $GNVC 4Q14 Call – Doug, CEO: Recently entered into collaboration with TheraBiologics to develop next-gen neural stem cell therapy for cancer

  19. $GNVC 4Q14 Call – Doug, CEO: Last year, clinical development began for CGF166, the lead product candidate in collaboration with Novartis.

  20. $GNVC 4Q14 Call Participants: Douglas Swirsky, CEO; Douglas Brough, CSO; and James Lambert, CFO.

  21. $GNVC 4Q14 PR: “Anticipate cash burn of $5-7MM for 2015 & believe resources are sufficient to fund operations into 2017,” said Doug, CEO.

  22. $GNVC 4Q14 PR: G&A expenses $1.3MM vs. $1.1MM in 4Q13. As of March 20, 2015, unaudited cash, cash equivalents, & investments $13MM.

  23. $GNVC 4Q14 PR: EPS $0.11 vs. loss per share $0.07 in 4Q13. R&D expenses $0.6MM vs. $0.1MM in 4Q13.

  24. $GNVC 4Q14 PR: Revenues $3.5MM vs. $0.1MM in 4Q13. Net income $1.7MM vs. net loss of $0.9MM in 4Q13.

  25. $GNVC healthy volume this morning. Keep the momentum.